Posted: Tuesday, July 5, 2022
The University of Texas MD Anderson Cancer Center, Houston, has announced a strategic research and development alliance with Turning Point Therapeutics, with the goal of expanding the evaluation of two investigational small molecules. The initial focus will be on monotherapy and potential combinations—including chemotherapy and immunotherapies—with repotrectinib, a kinase inhibitor targeting ROS1 and NTRK oncogenic drivers of non–small cell lung cancer (NSCLC). The alliance will also study elzovantinib (TPX-0022), a kinase inhibitor that targets MET, CSF1R, and SRC .
Repotrectinib is currently being observed in the TRIDENT-1 study, a registrational phase I/II study, and elzovantinib is currently being studied in the phase I trial SHIELD-1. Under the terms of the alliance’s 5-year agreement, collaborative preclinical and clinical studies will be conducted in several solid tumors, including NSCLCs, gastrointestinal malignancies, and endocrine cancers. These collaborative studies will be overseen by a joint steering committee for which Turning Point Therapeutics will provide funding, study materials, and other ongoing support throughout the term of the alliance.
“There is a major unmet need to develop effective next-generation targeted therapies for cancer patients with oncogene-driven solid tumors, particularly those with mutations that render them resistant to our current therapies,” said John V. Heymach, MD, PhD, Chair of Thoracic/Head & Neck Medical Oncology at MD Anderson.